Comparison of Surgical Outcome After Ahmed Valve Implantation for Patients With and Without Fluocinolone Intravitreal Implant (Retisert)
- 1 September 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 25 (9) , e772-e776
Abstract
Patients who received a Retisert implantation had lower IOP and used fewer glaucoma eye drops compared with control eyes at 1-year post-Ahmed valve surgery. This study suggests that long-term, slow-release corticosteroid medication from Retisert (fluocinolone acetonide) may improve the surgical outcome for patients with an Ahmed valve implantation and/or Retisert helps control uveitis in patients with uveitic glaucoma receiving Ahmed valves.Keywords
This publication has 12 references indexed in Scilit:
- The Outcomes of Primary Scleral Buckling during Repair of Posterior Segment Open-Globe InjuriesBioMed Research International, 2014
- A Comparison Between the Fluocinolone Acetonide (Retisert) and Dexamethasone (Ozurdex) Intravitreal Implants in UveitisJournal of Ocular Pharmacology and Therapeutics, 2013
- The Changing Face of Primary Open-Angle Glaucoma in the United States: Demographic and Geographic Changes From 2011 to 2050American Journal of Ophthalmology, 2012
- Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular GlaucomaJournal of Glaucoma, 2012
- Tube shunt complications and their preventionCurrent Opinion in Ophthalmology, 2009
- Ahmed Valve Implantation with Adjunctive Mitomycin C and 5-Fluorouracil: Long-term OutcomesAmerican Journal of Ophthalmology, 2008
- Fluocinolone Acetonide Implant (Retisert) for Noninfectious Posterior UveitisOphthalmology, 2006
- Ethnic differences in glaucoma: prevalence, management, and outcomeCurrent Opinion in Ophthalmology, 2005
- Antifibrotics and Wound Healing in Glaucoma SurgerySurvey of Ophthalmology, 2003
- Bias reduction of maximum likelihood estimatesBiometrika, 1993